FDA Approves Enhertu for Neoadjuvant and Adjuvant HER2‑Positive Early Breast Cancer

Why It Matters

The FDA’s dual approval marks the first time an ADC has been cleared for both neoadjuvant and adjuvant use in HER2‑positive early breast cancer, reshaping treatment algorithms that have long relied on chemotherapy followed by trastuzumab alone. By delivering higher pCR rates and a substantial IDFS advantage, Enhertu offers patients a more effective chance of cure while reducing reliance on traditional cytotoxic regimens. Beyond patient outcomes, the decision signals regulatory openness to surrogate‑endpoint‑driven approvals for high‑risk early‑stage cancers, a trend that could hasten the introduction of innovative therapies across oncology. Competitors will need to generate comparable efficacy data or risk losing market share in a segment that represents a sizable portion of global breast‑cancer revenue.

Key Takeaways

• FDA approved Enhertu for neoadjuvant treatment of stage 2‑3 HER2‑positive early breast cancer
• FDA approved Enhertu for adjuvant treatment of patients with residual invasive disease after standard therapy
• DESTINY‑Breast11 showed pCR of 67.3% vs 56.3% for control (Δ 11.2%)
• DESTINY‑Breast05 demonstrated 53% reduction in invasive‑disease‑free survival events versus T‑DM1
• Enhertu added as Category 1 NCCN guideline recommendation for adjuvant HER2‑positive disease

Pulse Analysis

Enhertu’s expansion into early‑stage disease reflects a broader shift toward using antibody‑drug conjugates earlier in the cancer care continuum. Historically, ADCs were reserved for metastatic settings where incremental benefit justified higher toxicity and cost. The robust pCR and IDFS data suggest that the therapeutic window for ADCs may be wider than previously thought, encouraging sponsors to design trials that target curative intent.

From a market perspective, the partnership between Daiichi Sankyo and AstraZeneca leverages complementary strengths: Daiichi’s discovery platform and AstraZeneca’s global commercial infrastructure. This collaboration positions them to out‑maneuver single‑company rivals that may lack the scale to launch a new indication across multiple regions simultaneously. However, the pricing strategy will be critical; if the product is priced significantly above T‑DM1, payers could push back, especially in value‑based contracts that tie reimbursement to real‑world outcomes.

Looking forward, the approval could catalyze a wave of ADC development for neoadjuvant and adjuvant indications, prompting regulators to refine guidance on surrogate endpoints like pCR. For clinicians, the decision adds a potent tool to the HER2 armamentarium, but also introduces complexity in sequencing therapies. The next few years will likely see head‑to‑head trials comparing Enhertu directly with T‑DM1 and newer HER2‑targeted agents, shaping the standard of care for early‑stage HER2‑positive breast cancer.